Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Stock Performance

Shares of AVDL traded up $1.09 during mid-day trading on Tuesday, hitting $7.40. 48,993 shares of the company's stock were exchanged, compared to its average volume of 806,016. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 2.11. Avadel Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $11.59. The business's 50 day moving average is $3.54 and its two-hundred day moving average is $5.17. The firm has a market capitalization of $436.90 million, a P/E ratio of -4.47 and a beta of 1.51.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.01). On average, equities analysts expect that Avadel Pharmaceuticals will post -1.33 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on AVDL. Oppenheimer dropped their price target on shares of Avadel Pharmaceuticals to $13.00 in a research note on Friday, May 27th. SVB Leerink decreased their price objective on shares of Avadel Pharmaceuticals from $18.00 to $6.00 and set an "outperform" rating for the company in a research note on Friday, May 27th. Stifel Nicolaus raised their price objective on Avadel Pharmaceuticals from $2.00 to $5.00 in a report on Tuesday, July 19th. HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Avadel Pharmaceuticals in a report on Friday, July 1st. Finally, Needham & Company LLC dropped their price target on Avadel Pharmaceuticals from $14.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, May 31st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $9.17.

Insider Transactions at Avadel Pharmaceuticals

In other news, CFO Thomas S. Mchugh acquired 50,000 shares of the stock in a transaction that occurred on Friday, May 27th. The shares were purchased at an average cost of $2.14 per share, for a total transaction of $107,000.00. Following the transaction, the chief financial officer now directly owns 71,500 shares in the company, valued at approximately $153,010. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Avadel Pharmaceuticals news, Director Eric J. Ende bought 15,000 shares of the company's stock in a transaction on Tuesday, May 31st. The shares were bought at an average price of $2.16 per share, for a total transaction of $32,400.00. Following the transaction, the director now owns 114,900 shares of the company's stock, valued at approximately $248,184. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Thomas S. Mchugh purchased 50,000 shares of Avadel Pharmaceuticals stock in a transaction dated Friday, May 27th. The stock was acquired at an average cost of $2.14 per share, with a total value of $107,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 71,500 shares in the company, valued at $153,010. The disclosure for this purchase can be found here. Insiders purchased 75,000 shares of company stock worth $155,400 over the last 90 days. 3.20% of the stock is currently owned by insiders.